Real-life data on clinical characteristics, treatments and outcomes of patients with newly diagnosed advanced-stage ovarian cancer: an observational study from Belgium
Open Access
- 8 January 2026
- journal article
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (2) , 95-105
Abstract
Data about the clinical management of patients with ovarian cancer (OC) in real-world settings are scarce. This study documents baseline characteristics, treatments, and clinical outcomes in a real-world population of women with newly diagnosed advanced-stage OC in Belgium. This observational study, conducted at four hospitals in Belgium, retrospectively enrolled 120 women with FIGO (International Federation of Gynecology and Obstetrics classification) stage III or IV high-grade serous or endometrioid OC diagnosed between 2007 and 2018. Treatment outcomes, response to therapy, and patient survival were followed up until 20 months after diagnosis. Of 113 patients with a clinical response assessment, 49.6% were diagnosed with a stage IV disease, 53.1% underwent interval debulking surgery, 98.2% received any type of chemotherapy, and 35.4% received bevacizumab. Deleterious mutations in breast cancer susceptibility genes (BRCA1/BRCA2) were detected in 12/84 (14.3%) patients. After primary or interval debulking surgery, 50.0% and 60.0% of stage III, and 66.7% and 80.0% of stage IV patients had no visible residual disease, respectively. Following chemotherapy, 59.3% of patients had complete clinical response and/or no visible residual disease. Until month 20 of follow-up, 37.2% of patients were disease-free. Until 2018, surgical resection followed by first-line chemotherapy and bevacizumab use comprised the cornerstone therapy for newly diagnosed FIGO stage IV OC in Belgium. Clinical response and progression-free survival rates were relatively high. The patients' BRCA1/BRCA2 status was insufficiently characterized, likely reflecting the lack of perceived relevance of BRCA1/BRCA2 mutations for OC treatment before adoption of targeted therapies in clinical practice.Keywords
Funding Information
- AstraZeneca
This publication has 33 references indexed in Scilit:
- Optimal bevacizumab treatment strategy in advanced ovarian cancer: A reviewCancer Treatment Reviews, 2025
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialAnnals of Oncology, 2024
- LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)Annals of Oncology, 2022
- Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trialAnnals of Oncology, 2022
- Real‐life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)Cancer, 2022
- Screening for Ovarian CancerJAMA, 2018
- Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancerEuropean Journal of Cancer, 2017
- RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupEuropean Journal of Cancer, 2016
- Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CTEuropean Radiology, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009